Beijing Cancer hospital-Urinary Surgery ( Site 0406)

Beijing, Beijing Municipality 100142

0 studies enrolling now · 1 studies all time

What they study most

Carcinoma, Renal Cell

Studies at this site

• A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) — Running, not enrolling